Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose
Hung-Chun Tung,Jong-Won Kim,Junjie Zhu,Sihan Li,Jiong Yan,Qing Liu,Imhoi Koo,Sergei A. Koshkin,Fuhua Hao,Guo Zhong,Meishu Xu,Zehua Wang,Jingyuan Wang,Yixian Huang,Yue Xi,Xinran Cai,Pengfei Xu,Songrong Ren,Takanobu Higashiyama,Frank J. Gonzalez,Song Li,Nina Isoherranen,Da Yang,Xiaochao Ma,Andrew D. Patterson,Wen Xie
DOI: https://doi.org/10.1126/scitranslmed.adk8446
IF: 17.1
2024-09-27
Science Translational Medicine
Abstract:Activation of extracellular matrix–producing hepatic stellate cells (HSCs) is a key event in liver fibrogenesis. We showed that the expression of the heme-thiolate monooxygenase cytochrome P450 1B1 (CYP1B1) was elevated in human and mouse fibrotic livers and activated HSCs. Systemic or HSC-specific ablation and pharmacological inhibition of CYP1B1 attenuated HSC activation and protected male but not female mice from thioacetamide (TAA)–, carbon tetrachloride (CCl 4 )–, or bile duct ligation (BDL)–induced liver fibrosis. Metabolomic analysis revealed an increase in the disaccharide trehalose in CYP1B1-deficient HSCs resulting from intestinal suppression of the trehalose-metabolizing enzyme trehalase, whose gene we found to be a target of RARα. Trehalose or its hydrolysis-resistant derivative lactotrehalose exhibited potent antifibrotic activity in vitro and in vivo by functioning as an HSC-specific autophagy inhibitor, which may account for the antifibrotic effect of CYP1B1 inhibition. Our study thus reveals an endobiotic function of CYP1B1 in liver fibrosis in males, mediated by liver-intestine cross-talk and trehalose. At the translational level, pharmacological inhibition of CYP1B1 or the use of trehalose/lactotrehalose may represent therapeutic strategies for liver fibrosis.
cell biology,medicine, research & experimental